AACR 2023 Highlights Novel Research in NSCLC and ES-SCLC
Research presented at AACR 2023 highlighted a potential new standard of care for NSCLC and other novel treatments for NSCLC and ES-SCLC.
American Association for Cancer Research (AACR)
Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Surufatinib Plus Toripalimab Deemed Potential First-Line Option for NSCLC
First-line treatment with surufatinib and toripalimab provided disease control in 100% of patients with advanced, PD-L1+ NSCLC.
Salmonella-IL2 May Improve Upon FOLFIRINOX in Stage IV Pancreatic Cancer
Salmonella-IL2 plus FOLFIRINOX may be more effective than FOLFIRINOX alone in patients with stage IV pancreatic cancer, a phase 2 study suggests.
MEDI1191 Plus Durvalumab Appears Safe, Active in Advanced Solid Tumors
Combination treatment with MEDI1191 and durvalumab has demonstrated activity in a phase 1 trial of patients with advanced solid tumors.
ALLO-316, a CAR T-Cell Therapy, Shows Activity in Advanced RCC
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
Bispecific CAR T-Cell Therapy Has “Robust” Activity in Non-Hodgkin Lymphoma
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
AFM13 Proves Active in Relapsed/Refractory PTCL, Especially AITL
The bispecific antibody AFM13 elicits responses in patients with relapsed/refractory peripheral T-cell lymphoma, a phase 2 study suggests.
Petosemtamab Shows “Clinically Meaningful Activity” in Advanced HNSCC
Petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study suggests.
Hereditary Cancer Syndromes Often Missed Under Current Screening Guidelines
Following genetic screening guidelines may cause clinicians to miss as many as 40% of patients with high-risk hereditary cancer syndromes, a study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in AACR 2023
Loading... 
Loading...